What Is IGF-1 DES?

1. How does IGF-1 DES work?

IGF-1 binds to receptors on cells that influence growth, survival and metabolism. Separate proteins, called IGF-binding proteins or IGFBPs, bind IGF-1 and regulate its availability. Receptors transmit the signal; binding proteins affect how much growth factor can reach them.

Removing the first three amino acids changes this second interaction. In Bagley and colleagues’ 1989 experiments, DES interacted much less strongly with the binding proteins researchers tested. That helped explain its increased activity in rat muscle precursor cells, called myoblasts.

“Doesn’t bind to any IGFBPs” goes too far. In a 1995 goat infusion study, labeled DES still bound to IGFBP-3. Binding depends on which protein and experimental conditions are involved. A useful description is reduced binding, without assuming that every carrier interaction disappears.

The FDA substance registry also lists DES as 4–70 human IGF-I. That notation identifies the amino acids left after the deletion. DES contains the remaining 67 residues; it is not the three-amino-acid fragment that was removed.

2. Where does the “10 times stronger” claim come from?

In the 1989 muscle-cell assay, native IGF-1 produced half of its maximal protein-synthesis response at 13 ng/mL. DES reached that point at 1.5 ng/mL, roughly one ninth of the concentration.

That is a potency comparison for one response under specified laboratory conditions. It does not mean the cells made nine times as much protein, or that a person would gain nine times as much muscle. Potency describes how much compound it takes to reach a response; the maximum response is a separate measurement.

A claim that DES is universally “10× stronger” drops the cell type, binding proteins and outcome from the result. Those details determine whether the comparison applies anywhere else.

3. What do the animal studies show?

DES produced measurable anabolic effects in animals under substantial physiological stress. These experiments help explain the interest in it, while also showing why body-weight gain cannot be counted entirely as new muscle.

The bowel-resection study also found heavier kidneys in all treatment groups and a heavier thymus with DES. In the dexamethasone experiment, IGF treatments increased gut weight by up to 45%, particularly with the analogues. The authors noted that gut protein turnover could contribute to a urinary marker often used to assess muscle breakdown.

These findings support investigating DES in wasting conditions. They do not supply an expected increase in biceps size, strength or lean mass for a healthy adult.

Targeted PubMed and Europe PMC searches, checked September 22, 2026, did not identify a controlled human DES trial establishing muscle gain, fat loss or recovery. Studies adding DES to human cells or blood samples are laboratory experiments, not trials in people receiving DES.

4. Does IGF-1 DES build muscle at the injection site?

Local growth is one of the most attractive DES claims for someone with a lagging body part. Establishing it would require evidence that the treated muscle grows more than a suitable comparison muscle or control group, with training and other drugs accounted for. The studies above did not test that question in humans.

Reduced IGFBP binding does not show that the peptide remains confined to an injected muscle. The systemic glucose effects in animals also make a blanket promise of local-only action difficult to justify.

“Hyperplasia” means an increase in cell number. Muscle precursor cells multiplying in a dish cannot establish that adult humans grow extra functional muscle fibers after a DES cycle. Larger fibers, more fibers and a temporary increase in muscle circumference are different outcomes.

For anyone tracking results, a post-workout pump is especially weak evidence. Circumference immediately after training cannot distinguish lasting tissue growth from short-term changes in blood flow and fluid. Before-and-after reports become harder to interpret when DES starts alongside HGH, testosterone, more calories or a different training program.

5. IGF-1 DES half-life and the 20–30-minute claim

The papers reviewed here do not validate a 20–30-minute DES half-life in humans. A half-life describes how quickly a measured concentration falls under particular conditions. It does not automatically tell you when every biological effect ends.

The 1997 pig and marmoset experiments illustrate the problem. Despite faster clearance from circulation, low-binding IGF variants produced more sustained glucose suppression than native IGF-1. Across the variants and models, cumulative glucose suppression over four hours was approximately four to eight times greater. That result cannot define a human DES risk window, but it undermines the assumption that fast clearance guarantees brief effects.

Laboratory detection is another separate measurement. Mongongu et al. (2021) detected unchanged DES up to 24 hours after intramuscular administration in rats. This was an analytical detection experiment. It neither establishes a 24-hour half-life nor predicts how long a human effect lasts.

A half-life graph built around an unvalidated number will still draw a precise curve. The uncertainty lies in the input, even if the calculation is correct.

6. IGF-1 DES vs LR3, HGH and mecasermin

DES is often presented as the local, short-acting choice and LR3 as the systemic, long-acting choice. No controlled human comparison reviewed here establishes that division or a better muscle-to-risk tradeoff. The LR3 guide examines why its own widely repeated half-life figure needs scrutiny.

The Increlex label covers children aged two and older with severe primary IGF-1 deficiency, or GH gene deletion with neutralizing antibodies to GH. That approval does not extend to DES, adult bodybuilding or combinations marketed as peptide stacks.

7. Side effects, blood sugar and cancer questions

Hypoglycemia, or low blood sugar, has direct DES-specific animal evidence. Human studies have not established its frequency or severity after DES use. Lower glucose is not automatically better glucose control, and the animal results do not establish DES as a treatment for insulin resistance.

Related human drug data add context. The mecasermin label warns about severe hypoglycemia, including seizures, allergic reactions, intracranial hypertension and malignant neoplasia. These warnings concern mecasermin; they cannot be converted into DES adverse-event percentages. Confusion, loss of consciousness or a seizure after an injection requires emergency medical attention.

There is also a DES-specific cancer experiment. Hadsell and colleagues (2000) studied mice genetically engineered to produce DES in mammary tissue. By 23 months, 53% of the DES-expressing mice had developed mammary adenocarcinomas. Adding a mutant p53 gene accelerated tumor appearance.

Continuous tissue production in a genetically engineered mouse differs substantially from an injected human exposure. That percentage is not a human cancer-risk estimate. The study does, however, give a concrete reason to investigate unwanted growth and cell-survival effects. Human data establish neither a safe cycle length nor that short exposure avoids those concerns.

8. Dosage, cycles, recovery and product quality

There is no validated DES bodybuilding dose, cycle length or pre-workout versus post-workout schedule. Continuous animal infusions cannot establish an intermittent human injection regimen. Nor can a pediatric mecasermin prescription be adjusted by a cell-culture potency ratio to produce a DES dose.

The same gap applies to injury recovery and fat loss. The cited studies do not provide a return-to-training timeline, evidence of repaired human tendons or a dependable reduction in body fat. They also do not establish DES as a way to prevent muscle loss during GLP-1 treatment.

Product quality adds a separate uncertainty. In their 2021 IGF-analogue analysis, Mongongu and colleagues found oxidized peptide forms in black-market products. The study included DES, LR3 and R3 and was designed to improve analytical detection. It cannot tell us how often every seller’s products contain degraded material or what a particular vial contains.

A purity percentage alone does not establish identity, quantity, sterility or biological activity. Reconstitution arithmetic cannot answer those questions either. Research handling instructions describe how a laboratory uses a reagent; they do not establish that the finished preparation is suitable for injection.

9. Approval, sport and keeping useful records

DES has no FDA-approved use identified in this review. Its FDA UNII entry is a substance identifier. FDA explicitly states that having a UNII does not imply regulatory review or approval.

For tested athletes, WADA’s 2026 Prohibited List includes IGF-1 and its analogues in section S2.3, prohibited both in and out of competition. A short claimed half-life does not change that classification.

If you are discussing an exposure with a clinician, bring the product label, batch details, dates, other drugs or peptides, and any symptoms. A tracking record is more useful when it includes unwanted effects and changes in training, calories and body weight. Keep laboratory reports with their sampling dates and methods so the clinician can assess what each result measures.

10. IGF-1 DES FAQ

• What is IGF-1 DES used for?

  Researchers use IGF-1 DES to study growth-factor signaling and binding proteins. Muscle gain, injury recovery and fat loss are proposed enhancement uses without established benefits in controlled human trials.

• What does DES mean in IGF-1 DES?

  Des(1-3) identifies the removal of amino acids 1 through 3 from IGF-1: glycine, proline and glutamate. The remaining peptide has 67 amino acids. IGF1 DES and IGF DES usually refer to this same molecule.

• Is IGF-1 DES 10 times stronger than IGF-1?

  In one rat muscle-cell experiment, DES reached a half-maximal protein-synthesis response at 1.5 ng/mL versus 13 ng/mL for IGF-1. That is about a ninefold concentration difference in that assay, not evidence of tenfold muscle gain in people.

• Does IGF-1 DES cause local muscle growth?

  No controlled human study identified in this review established extra growth in an injected muscle. Reduced binding to carrier proteins does not demonstrate that DES stays at the injection site.

• What is the half-life of IGF-1 DES?

  The commonly quoted 20–30-minute figure is not a validated human half-life in the research reviewed here. Blood concentration, biological effects and laboratory detectability describe different time courses.

• Is IGF-1 DES better than LR3?

  DES has 67 amino acids; LR3 has 83 and different structural modifications. Both bind IGF-binding proteins less strongly than native IGF-1. No controlled human comparison establishes which produces better muscle gains or fewer adverse effects.

• What is the best IGF-1 DES dosage or cycle?

  There is no validated human enhancement dose, cycle length, injection schedule or post-workout window. Animal infusion experiments and prescriptions for mecasermin cannot establish a DES protocol.

• Can IGF-1 DES cause hypoglycemia?

  DES lowered blood glucose in pigs and marmosets. Human frequency and severity are unknown. Short circulation time should not be treated as protection from sustained glucose effects.

• Does IGF-1 DES cause cancer?

  Its human cancer risk is unknown. A genetically engineered mouse study linked sustained DES production in mammary tissue with tumor development, but that model cannot quantify the risk of injections in people.

• Is IGF-1 DES FDA-approved or allowed in tested sport?

  DES has no FDA-approved use. An FDA substance identifier does not mean approval. WADA's 2026 Prohibited List includes IGF-1 and its analogues, prohibited both in and out of competition.

11. Sources